Efficacy and safety of denosumab versus zoledronic acid in delaying skeletal-related events in patients with gastrointestinal cancer, pancreas-biliary system cancer, and other rare cancers

Efficacy and safety of denosumab versus zoledronic acid in delaying skeletal-related events in patients with gastrointestinal cancer, pancreas-biliary system cancer, and other rare cancers

Background: Bone is a metastatic site for various types of cancer. Cancer patients in whom bone metastases progress often have skeletal-related events (SREs). Denosumab and zoledronic acid are both bone-modifying agents that prevent the occurrence of SREs. Denosumab has been shown to be superior to...

Full description

Bibliographic Details
Main Authors:	Hiroo Imai, Ken Saijo, Hideharu Yamada, Kota Ohuchi, Yoshinari Okada, Keigo Komine, Masahiro Takahashi, Shin Takahashi, Masanobu Takahashi, Hideki Shimodaira, Chikashi Ishioka
Format:	Article
Language:	English
Published:	Elsevier 2017-03-01
Series:	Journal of Bone Oncology
Subjects:	Denosumab Zoledronic acid Bone metastases Gastrointestinal cancer Pancreas-biliary system cancer Rare cancers
Online Access:	http://www.sciencedirect.com/science/article/pii/S221213741630063X

Similar Items

Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years
by: Chi Zhang, et al.
Published: (2018-11-01)

Cost-effectiveness Analysis of Denosumab in the Prevention of Skeletal-related Events in Patients with Prostate Cancer in Kazakhstan
by: Carina Bektur, et al.
Published: (2014-12-01)

Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion
by: Jean-Jacques Body, et al.
Published: (2018-09-01)

Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned
by: Christian Thomas, et al.
Published: (2016-08-01)

Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials
by: Lianghai Jiang, et al.
Published: (2021-06-01)

Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients
by: Polyzois Makras, et al.
Published: (2021-12-01)

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial
by: Li, S., et al.
Published: (2022)

USE OF ZOLEDRONIC ACID AND A RАNK LIGAND INHIBITOR IN THE PALLIATIVE TREATMENT OF CANCERS OF THE PROSTATE WITH BONE METASTASES
by: S. V. Mushigin, et al.
Published: (2014-07-01)

USE OF ZOLEDRONIC ACID AND A RАNK LIGAND INHIBITOR IN THE PALLIATIVE TREATMENT OF CANCERS OF THE PROSTATE WITH BONE METASTASES
by: S. V. Mushigin, et al.
Published: (2014-07-01)

A Multi-Institutional Randomized Controlled Trial to Investigate Whether Zoledronate Prevents Bone Loss After Discontinuation of Denosumab: The Study Protocol of Denosumab Sequential Therapy (DST) Trial
by: Chia-Che Lee, et al.
Published: (2021-09-01)

Potential protective effect of zoledronic acid when switching from long-term therapy of osteoporosis with denosumab
by: O. V. Yakushevskaya
Published: (2021-01-01)

Denosumab for Breast Cancer with Bone Metastases-Induced Hypercalcemia Complicated with Acute Renal Failure
by: Chen-Yu Kuo, et al.
Published: (2015-06-01)

Management of bone metastases in refractory prostate cancer – role of denosumab
by: Paller CJ, et al.
Published: (2012-09-01)

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer
by: Megan M. Tu, et al.
Published: (2021-05-01)

Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
by: Yee AJ, et al.
Published: (2012-09-01)

Severe Hypophosphatemia Following Denosumab Administration in a Hemodialysis Patient with Progressive Prostate Cancer
by: Hiroshi Masuda, et al.
Published: (2017-07-01)

Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells
by: Hsien Liu, et al.
Published: (2019-02-01)

Quality of life is an important criterion for the efficiency of targeted therapy for metastatic skeletal involvement in breast cancer
by: T. Yu. Semiglazova, et al.
Published: (2014-07-01)

Zoledronic acid effects interleukin-6 expression in hormone-independent prostate cancer cell lines
by: Layka A. Asbagh, et al.
Published: (2008-06-01)

Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
by: Vittorio Fusco, et al.
Published: (2018-09-01)

EFFICACY OF ZOLEDRONIC ACID IN THE PREVENTION OF BONE METASTASES IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER
by: T. N. Musaev, et al.
Published: (2014-07-01)

Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells
by: Salah A. Sheweita, PhD, et al.
Published: (2021-02-01)

EFFICACY OF ZOLEDRONIC ACID IN THE PREVENTION OF BONE METASTASES IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER
by: T. N. Musaev, et al.
Published: (2014-07-01)

SUBTROCHANTERIC FRACTURE IN A PATIENT RECEIVING ZOLEDRONIC ACID THERAPY FOR METASTATIC BREAST CANCER
by: Ishiguro, Naoki, et al.
Published: (2011)

Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid
by: Ibrahim Toni, et al.
Published: (2012-11-01)

BoOne HeEalth ManageEment in Patients with Early Breast Cancer: A Retrospective Italian Osteoncology Center “Real-Life” Experience (BOHEME Study)
by: Federica Recine, et al.
Published: (2019-11-01)

Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer
by: Arif Awan, et al.
Published: (2021-02-01)

Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives
by: Philippe Beuzeboc, et al.
Published: (2014-05-01)

Dosing of zoledronic acid with its anti-tumor effects in breast cancer
by: Xinmin Zhao, et al.
Published: (2015-09-01)

Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis
by: Yang Tao, et al.
Published: (2011-08-01)

Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cells
by: Maria Wilke, et al.
Published: (2014-03-01)

Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole
by: Sun SL, et al.
Published: (2016-10-01)

Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis
by: Elie Akoury, et al.
Published: (2019-08-01)

Denosumab for management of severe hypercalcemia in primary hyperparathyroidism
by: Anna Eremkina, et al.
Published: (2020-10-01)

Remarkable Regression of an Osteolytic Lesion of Large Cell Lung Cancer Treated with Zoledronic Acid: A Case Report
by: Sadayuki Kawai, et al.
Published: (2012-05-01)

OUR EXPERIENCE WITH ZOLEDRONIC ACID IN THE TREATMENT OF PATIENTS WITH NON- SMALL CELL LUNG CANCER AND BONE METASTASES
by: Deyan N. Davidov
Published: (2013-04-01)

PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model
by: Yuan Li, et al.
Published: (2018-06-01)

Functionalized Selenium Nanotherapeutics Synergizes With Zoledronic Acid to Suppress Prostate Cancer Cell Growth Through Induction of Mitochondria-Mediated Apoptosis and Cell Cycle S Phase Arrest
by: Yulin An, et al.
Published: (2021-06-01)

Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer
by: Miriam Hegemann, et al.
Published: (2019-01-01)

Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid
by: Masashi Yanae, et al.
Published: (2017-09-01)